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ABSTRACT 
INTRODUCTION 
 Dyslipidemias are an emerging global health challenge yet, they remain 
underdiagnosed and under treated. Many newer therapies are being discovered for 
treating these dyslipidemias. Studies have shown that Biotin a B complex vitamin 
has favourable effects on the plasma lipid profile of diabetic and non diabetic 
subjects.This study was conducted to find out the effect of pharmacological doses 
of biotin on plasma lipid profile of  patients with secondary dyslipidemias. 
AIM AND OBJECTIVES 
 The  objective of this study was to determine and  compare the percentage 
change from baseline in lipid parameters  at weeks 1
st
 ,2
nd
 ,4
th
  and 6
th   
week  
between the two groups – control group which received Atorvastatin 20 mg per 
day and study group which received Atorvastatin 20 mg per day with Biotin 5 
mg/day.  
METHODOLOGY 
 60 subjects in the age group of 45-60 yrs with secondary dyslipidemia 
meeting the inclusion criteria were enrolled after getting a written informed 
consent. After performing baseline laboratory investigations and lipid profile they 
were randomized into two groupsThe control group. received Atorvastatin 20 mg  
alone  and the study group received Biotin 5mg along with  Atorvastatin 20 mg for 
6 weeks. Both the groups were followed up till 12 weeks. 
 RESULTS 
As compared with monotherapy, combination therapy resulted in greater 
reduction in total cholesterol (36%) (p<0.001), greater reduction in LDL 
cholesterol (42%) (p<0.001), greater reduction in triglycerides (26.73%) (p<0.001) 
and greater reduction in VLDL (36%) (p=0.839) at 6 weeks. Addition of Biotin 
also resulted in greater rise in HDL (4.17%), but the difference was not statistically 
significant. The total cholesterol : HDL ratio became  3.54 in the combination  
group which was in the desirable level. Adverse events were also less in the 
combination therapy. 
CONCLUSION 
Combination therapy  of  Biotin 5mg  with Atorvastatin  20 mg  is more 
efficacious  than Atorvastatin alone  in terms of reduction in Total cholesterol, 
LDL cholesterol and triglycerides. Biotin is a  safe  and well tolerated  adjuvant 
hypolipidemic agent in secondary dyslipidemias. 
KEY WORDS 
Biotin, hyperlipoproteimias,statins,fibrates,lipid profile,creatine kinase 
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INTRODUCTION 
  Dyslipidemias and their complications are now emerging as 
an important public health challenge globally.
1
 It has been predicted that 
by 2020, cardiovascular diseases secondary to dyslipidemias will be the 
largest causes of disability and death in the developing countries,
2
 
especially in India, with 2.6 million Indians predicted to die due to 
cardiovascular diseases.
3
 
 The role of these lipoprotein abnormalities in the causation 
and maintanence of atherosclerosis and their primary role in 
cardiovascular morbidity and mortality is well known and cannot be 
underestimated.
4
  
 Lipid lowering therapies including pharmacological and non-
pharmacological therapies have a significant role in the primary & 
secondary prevention of cardiovascular disorders. 
The HMG Co-A reductase inhibitors are the first line  and widely 
used  pharmacological agents, but  they still  have some limitations. 
Patients are usually under treated due to the fear of adverse events and 
donot achieve their LDL goals. After prolonged use and even increased 
doses  statins produce a ceiling dose effect due to feed  back 
compensatory induction of HMG Co A reductase enzyme.
5
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Studies have shown that clinical use of effective pharmacological 
strategies for lowering LDL have reduced cardiovascular events. But still 
they prevent only a minority of these endpoints. Consequently other 
aspects of lipid profile have become tempting targets for addressing the 
residual burden of disease.
6
 
Other newer agents in development include cholesteryl ester 
transfer protein inhibitors, antisense oligonucleotides and PPAR-agonists 
but the trial results are not satisfactory. 
Recently, more vitamin mediated effects are being discovered at 
gene expression level.
7 
Of these, Biotin has shown to regulate expression 
of genes which are important in intermediary metabolism.  
Biotin is a B complex vitamin now being used for treating 
dermatitis, brittle nails, hair loss and biotin deficiency associated 
parentral alimentation.   
Studies investigating the effect of Biotin administration  in  small 
groups of patients have concluded that pharmacological doses of biotin 
decrease hypertriglyceridimia.
8 
It has also been shown that Biotin 
supplementation is effective in reducing  the plasma lipoproteins of 
diabetic & non diabetic subjects.
9
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This study was conducted to find out the effect of pharmacological 
doses of  Biotin on plasma lipid profile of dyslipidemic patients. If Biotin 
is proved to be an efficacious lipid lowering agent it would emerge as a 
cheaper and better tolerated adjuvant drug in the management of 
dyslipidemia. This will help in reducing the disease burden in the future. 
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REVIEW OF LITERATURE 
DYSLIPIDEMIA 
Synonyms: 
Hyperlipidemia, Hyperlipoproteinemia. 
Definition: 
 Dyslipidemia is a metabolic disorder of lipoproteins, which 
includes  overproduction or deficiency of lipoproteins.
10 
 It may manifest as   
 elevation of  total cholesterol (TC), 
 elevation  of  low density lipoprotein (LDL) cholesterol, 
 elevation of  triglyceride (TG) levels, 
 decrease in  blood HDL levels. 
Classification: 
Dyslipidemias can result from genetic defects in lipoprotein 
metabolism  (Primary Dyslipidemias ) or from some other underlying 
disorder that affects the circulating levels of lipids (Secondary 
Dyslipidemias). 
 
11 
 
Epidemiology:
 
Dyslipidemia is a common metabolic disorder. The prevalence of 
dyslipidemia has increased from 1.05% in 1960 to about 8 - 9.6% in 1990 
in the urban population of India.
11,12
  The National Health Survey, 
conducted in  U.S. during 1999 to 2000 showed that 25 % of adults had 
raised total cholesterol (> than 239.4 mg per dL) and were on lipid-
lowering medication.
13
 
Lipoprotein: 
 The term lipoprotein denotes a complex of lipids and protein, 
that are essential in the movement of cholesterol, triglycerides and fat 
soluble vitamins in the bloodstream. Structurally they contain a core of 
lipids like triglycerides and cholesterol esters which are hydrophobic, 
surrounded by phospholipids and unesterified  cholesterol which are 
hydrophilic.
14
  
The classification of lipoproteins is based on their relative 
densities. The various lipoprotein classes vary in their density, size and 
protein composition. The different classes of lipoproteins are  
1. The chylomicrons  
2. The very low density lipoproteins ( VLDL ) 
3. The low density lipoproteins ( LDL ) 
12 
 
4. The high density lipoproteins ( HDL )  
The density and size distribution of various 
 types of lipoprotein particles 
15 
 
Major lipoprotein classes
16 
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Of the various lipoproteins the smallest are the high density 
lipoproteins. They are also the most dense of all lipoproteins. The largest 
and least dense lipoprotein particles are the chylomicrons. The major 
transporters of plasma triglyceride are the chylomicrons and the very low 
density lipoproteins. Majority of the  plasma cholesterol is transported as 
cholesteryl esters in the low density lipoproteins  and the high density 
lipoproteins. 
Apolipoproteins: 
The protein moiety of the lipoproteins are known as  
apolipoproteins. The  apolipoproteins act as an essential component in the 
structure, assembly and function of lipoproteins. They play an important 
role in the  activation of  enzymes important in lipoprotein metabolism. 
They also act as  ligands for cell surface receptors.  
Various Apo lipoproteins are 
 Apo A-I, component of all HDL particles. It is synthesized 
in the liver and intestine. 
 Apo A-II, second important component of HDL, present on 
approximately 2/3 of all HDL particles.  
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 ApoB - major structural component of chylomicrons, 
VLDLs, IDLs, and LDLs. Usually apoB-48 is present in 
chylomicrons & apoB-100 is present on VLDL, IDL or 
LDL. ApoB-100 is synthesized by the human liver. ApoB-48 
is synthesized by the intestine. 
  ApoE seen in chylomicrons, VLDL, and IDL. They play a 
major role  in the metabolism and clearance of triglyceride-
rich particles.  
  C-series (apoC-I, apoC-II, and apoC-III). 
Lipoprotein Metabolism: 
Efficient transport of dietary lipids is carried out by the exogenous 
pathway of lipoprotein metabolism, through which the dietary 
triglycerides and cholesterol are delivered to various organs for utilization 
and storage.
17
  
The dietary lipids are packed in the cells of the small intestine into 
chylomicrons - which have a low cholesterol content & high 
triglycerides. Then these chylomicrons are secreted into the intestinal 
lymph and delivered directly to the systemic circulation through the 
thoracic duct. Chylomicron particles in systemic circulation are then 
acted upon by the enzyme lipoprotein lipase which is attached to the 
15 
 
endothelial surfaces of capillaries of various tissues like adipose tissue, 
heart, and skeletal muscle.  
The lipoprotein lipase hydrolyses the  triglycerides of chylomicrons 
and release the free fatty acids. The released free fatty acids are taken up 
by adjacent myocytes or adipocytes and can be  either oxidized to 
generate energy or can be  reesterified and stored as triglyceride.  
After the hydrophobic core is hydrolyzed, the triglycerides are 
distributed and the apolipoproteins are transferred to HDL the 
chylomicrons  progressively become smaller and form chylomicron 
remnants.  
These cholesterol rich chylomicron remnants then  bind to 
apolipoprotein E receptor present on the liver and endocytosed to 
serve as a dietary source of cholesterol.  
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LIPOPROTEIN METABOLISM
18 
 
ENDOGENOUS PATHWAY
19 
In this pathway the apoB-containing lipoproteins are secreted  from 
the liver and metabolised  in peripheral tissues .  
In the liver, the synthesized triglycerides and cholesterol esters are 
packed together with ApoB-100 to form VLDL. The VLDL are rich in 
triglycerides. During circulation in the blood the lipoprotein lipase 
hydrolyses the triglycerides of VLDL. This hydrolysis takes place in 
muscle, heart, and adipose tissue to  release free fatty acids and glycerol.  
After hydrolysis the VLDL remnants become intermediate density 
lipoproteins. The intermediate density lipoproteins contain equal amounts 
of cholesterol and triglyceride. 
17 
 
The intermediate density lipoproteins are taken up by the  the liver 
and are  acted by hepatic lipase  to form low density lipoproteins. This 
process consists of hydrolysis of the triglycerides and transfer of all 
apolipoproteins except apoB-100 to other lipoproteins. The low density 
lipoproteins contain a relatively high cholesterol content and are 
atherogenic. 
The cholesterol in LDL is responsible for more than one-half of the 
plasma cholesterol. During circulation nearly 70% of circulating LDL is 
cleared by liver by LDL receptor–mediated endocytosis. The absorbed 
LDL is hydrolysed within the lysosomes releasing cholesterol. 
Another lipoprotein similar to LDL in lipid and protein 
composition is Lipoprotein(a). It contains apolipoprotein(a), an additional 
protein. The site of synthesis of apoA is the liver. ApoA is  attached to 
apoB-100 by a disulfide linkage. The Lp(a) is cleared in the liver. 
Role of LDL cholesterol in atherogenesis: 
The term atherosclerosis is derived from Greek word for “gruel” 
and “hardening”. It a disease process charecterized by atheromas that 
protrude into the vascular lumen.
20
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These atherosclerotic plaques obstruct the blood flow and may 
weaken the underlying media and rupture to cause acute catastrophic 
events. 
Major risk factors: 
 Non modifiable 
1. Higher age 
2. Male  
3. Family history of atherosclerosis 
4. Genetic abnormalities 
 Modifiable 
1. Hyperlipidemia 
2. Hypertension 
3. Cigarrette smoking 
4. Diabetes mellitus 
5. C-reactive protein. 
Of the major modifiable risk factors hyperlipidemia is significant 
in that it can initiate atherosclerosis even when present as a single risk 
factor. 
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STRUCTURE OF EARLY ATHEROMATOUS 
PLAQUE
21 
 
 The plaque consists of a superficial fibrous cap which is 
composed of smooth muscle cells and dense collagen. There is a cellular 
region with more macrophages, T cells and smooth muscle cells below 
the fibrous cap. Below the cap is the necrotic core consisting of lipids like 
cholesterol and cholesterol esters, dead cell debris, organized thrombus 
and proteins. 
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Role of hyperlipidemia in atherosclerosis 
The excess of LDL cholesterol in blood 
1. Increases local production of reactive oxygen species which 
impairs endothelial cell function, accelerates decay of NO and 
increases local shear stress. 
2. Accumulates in the intima and are oxidized to form oxidized LDL. 
The oxidized LDL is ingested by macrophages to form foam cells. 
3. Stimulates the release of growth factors, cytokines & chemokines 
and increase monocyte recruitment.
22
 
High Density lipoproteins: 
High density lipoproteins are antiatherogenic as they help in the 
removal of cholesterol from the artery wall. They also inhibit the 
oxidation of LDL cholesterol.
 
HDL is synthesized and secreted from the intestine and the liver. The 
apolipoproteins - apoC and apo E are also synthesized from the liver. 
Initially the HDL particle consists of phospholipid bilayers and apoA and 
free cholesterol. The cholesterol which is effluxed from the cells is 
accepted by the HDL through the class B scavenger receptor and 
transported to liver for excretion. This process is called the reverse 
cholesterol transport. 
21 
 
Another important mechanism for cholesterol transport is through the          
ATP-binding cassette transporter A1 and G1 which help in the transport 
of cholesterol from the cells to the HDL. 
HDL concentrations are reciprocally related to the plasma 
triacylglycerol concentrations and are inversely related to the incidence of 
atherosclerosis. This is because the HDL levels reflect the efficiency of 
reverse cholesterol transport. 
DISORDERS OF LIPOPROTEIN METABOLISM: 
 Dyslipidemias that result from mutations of genes that encode 
defective  apoproteins (defective  apoB-100, apoC-II, apoA-V)  or alter 
the lipoprotein receptors like LDL receptors  on cells are called primary 
dyslipidemias or primary hyperlipoproteinemias. 
Primary Hyperlipoproteinemias: 
Fredrickson and Levy classified primary hyperlipoproteinemias 
into five types according to the type of lipoprotein particles that 
accumulate in the blood. 
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CLASSIFICATION OF PRIMARY HYPER 
LIPOPROTEINEMIAS
23
 
 
Other primary Disorders of lipoprotein metabolism: 
 Familial defective ApoB-100(FDB)                                                     
 Autosomal Dominant hypercholesterolemia due to mutations in 
Pcsk 9 (ADH-Pcsk9 or Adh 3) 
 Autosomal recessive Hypercholesterolemia 
 Sitosterolemia 
 Polygenic hypercholesterolemia 
 Apo –V deficiency 
 Hepatic lipase deficiency. 
23 
 
Secondary Hyperlipoproteinemias: 
Abnormal levels of lipoproteins occuring secondary to a variety of 
diseases are called secondary hyperlipoproteinemias. 
Obesity: 
 Obesity is associated with more adipocyte mass and decreased 
insulin sensitivity. This results in  
 Elevation in VLDL and Triglycerides 
 Elevated free fatty acids 
 Low levels of HDL 
Diabetes Mellitus: 
Diabetes Mellitus is a common cause of dyslipidemia. The 
associated abnormalities include
 
 Increased small dense LDL 
 Increased VLDL 
 Decreased HDL 
 Increased triglycerides 
 Enhanced oxidation of LDL 
 Increased triglyceride rich lipoprotein resulting from 
decreased lipoprotein lipase activity.  
24 
 
Lipodystrophy  
Lipodystrophy is associated with profound insulin resistance and 
elevated plasma levels of VLDL and chylomicrons. Partial lipodystropy 
can also present with dyslipidemia. 
Thyroid Disease 
 In hypothyroidism there  is reduction in hepatic LDL receptor 
function and delayed clearance of LDL. As a result there is elevation of 
plasma LDL, increased levels of circulating IDL and mild 
hypertriglyceridemia. In hyperthyroidism the plasma levels of LDL-C are 
reduced.  
Renal Disorders 
 In renal failure there is more triglyceride lipolysis and 
reduced clearance of remnants.  
 Nephrotic syndrome is associated with pronounced mixed 
hyperlipoproteinemia which is  due to  
 Increased hepatic production of VLDL 
 Decreased clearance of VLDLs 
 Increased LDL production 
25 
 
 End stage renal disease is associated with mild 
hypertriglyceridemia (less than 300 mg/dL ).This  due to the 
accumulation of VLDLs and remnant lipoproteins.  
 In renal transplants hyperlipoproteinemia occurs  due to the 
effect of the drugs administered for immunosuppression 
(cyclosporine and glucocorticoids) 
Liver Diseases: 
Liver is the principal site of lipoprotein metabolism. Hence liver 
diseases are associated with abnormalities in plasma lipid levels.  
 Hepatitis  is associated with mild to moderate 
hypertriglyceridemia       due to increased VLDL synthesis 
 Severe hepatitis and liver failure often leads to major 
reductions in cholesterol and triglycerides. 
 Cholestasis is associated with  severe hypercholesterolemia. 
Alcohol 
Alcohol consumption is associated with increase in plasma 
triglyceride levels. It also  increases  hepatic secretion of VLDL. Few 
studies show that regular alcohol use in smaller amounts  raises the HDL. 
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Estrogen 
 Increased VLDL and HDL synthesis is seen with estrogen 
administration leading to rise in plasma levels of both triglycerides and 
HDL-C. 
To minimize the effect of exogenous estrogen on lipids, low-dose 
preparations of estrogen or the estrogen patch can be used. 
Lysosomal Storage Diseases 
Cholesteryl ester storage disease (due to deficiency in lysosomal 
acid lipase) & glycogen storage diseases like von Gierke's disease are rare 
causes of secondary hyperlipidemias. 
Cushing's Syndrome 
Glucocorticoid excess seen in Cushing‟s syndrome  is associated 
with  
 Increased VLDL synthesis, 
 Hypertriglyceridemia, 
 Mild rise  in  LDL. 
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Drugs associated with hyperlipidemia: 
Significant alterations in lipid profile may occur secondary to many 
drugs. Commonly implicated drugs include 
 Thiazide diuretics 
 Atypical antipsychotics(Clozapine,Olanzepine) 
 Cyclosporine 
 Corticosteroids 
 Androgens 
 Betablockers 
 Retinoids 
 Protease inhibitors 
 Estrogen 
 Progesterone 
DIAGNOSIS 
 The recommendations of  NCEP ATPIII guidelines are that all 
adults ≥ 20 years of age  should undergo lipid screening.24 The screening 
includes a total lipid profile including total cholesterol, LDL cholesterol, 
triglycerides and HDL cholesterol which should be   repeated every 5 yrs. 
 
28 
 
 Patients usually   have a primary or genetic cause for their lipid 
disorder with secondary factors contributing to the hyperlipidemia.  
The first step in management is to determine the class or classes of 
lipoproteins that are increased or decreased in the patient. After 
classifying the hyperlipidemia, possible secondary causes of the 
hyperlipidemia should be ruled out. 
The family history, drug history and diet history should be noted 
and physical examination should be done to rule out secondary causes 
like diabetes, hypothyroidism, nephrotic syndrome or liver disease. 
Investigations to be done include 
 urinanalysis  
 serum thyroid stimulating hormone  
 serum alkaline phosphatase   
 glycosylated hemoglobin  
The  plasma lipoprotein abnormalities  are   firmly established risk 
factors of atherosclerosis and hence should be treated aggressively. 
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The following table lists the risk factor recognized by the current 
(Adult treatment panel III) guidelines. 
. 
 
 
According to the ATP III guidelines the patients are classified into one of 
the treatment strata according to the quantitative estimate of risk
24
. 
30 
 
UPDATED ATP III GOALS AND CUT POINT FOR 
THERAPY
25 
 
The first step to achieve the LDL goal involves lifestyle changes 
which includes specific diet and exercise recommendations. 
Diet 
Dietary modification is an important aspect  in managing  
dyslipidemia 
 Restriction of saturated fat and cholesterol in patients with 
elevated LDL levels. 
31 
 
 Restriction of simple carbohydrates for individuals with 
hypertriglyceridemia. 
 Restriction of total fat intake for severe 
hypertriglyceridemia.  
 Plant sterol and sterol esters reduce plasma LDL-C levels by 
10% when taken three times per day .  
 The addition of psyllium, soy protein, or Chinese red yeast 
rice
26
  to the diet. 
Weight Loss and Exercise 
 Weight reduction is associated with fall in plasma triglyceride and 
LDL-C levels and increase in HDL levels.  
Regular aerobic exercises can also have  positive change on lipids 
in large measure due to the associated weight reduction. 
Pharmacologic Treatment 
 In addition to  therapeutic life style changes, drug therapy is 
usually initiated to achieve the LDL goals. 
 
 
32 
 
 
 
Major classes of available drugs are 
Statins Lovastatin,  Pravastatin,  Simvastatin, 
Fluvastatin, Atorvastatin, Rosuvastatin 
 
Bile Acid Sequestrants  
 
Cholestyramine , colestipol 
,colesevelam 
Fibrates 
 
Gemfibrozil ,Fenofibrate ,Clofibrate 
Nicotinic acid. 
 
Niacin,acipimox 
Cholesterol absorbtion 
inhibitors 
 
Ezetimibe 
Cholesterol ester transfer 
protein inhibitors 
 
Torcetrapib 
33 
 
Phytosterols  
 
Statins are preferred usually for LDL reduction. Depending on the 
baseline LDL level, the starting dose of statin can be initiated and 
response checked in about 6 weeks and the dose of statin can be raised if 
necessary. 
Other lipid risk factors are low HDL cholesterol, elevated 
triglycerides and small LDL particles. This lipid triad is called 
atherogenic dyslipidemia. 
 
Atherogenic  dyslipidemia occurs as a component of metabolic 
syndrome.In such conditions non – HDL cholesterol ( Triglycerides, 
VLDL cholesterol and LDL cholesterol) represents a secondary target of 
therapy
27
. 
If after 6 weeks of therapy LDL goal is achieved and when Non 
HDL cholesterol goal is not achieved we can add a fibrate or nicotinic 
acid for triglyceride lowering
28
.  
Statins (HMG-CoA Reductase Inhibitors) 
34 
 
 Statins are competitive inhibitors of the HMG-CoA reductase 
enzyme which is the  rate limiting step in cholesterol biosynthesis. 
 Available statins are Mevastatin, Lovastatin, simvastatin, 
Pravasatatin, Fluvastatin, Atorvastatin and Rosuvastatin.   
ATORVASTATIN 
 Atorvastatin was discovered by Bruce D Roth, an American 
chemist in 1985. Unlike other statins it is a completely synthetic 
compound
29
. 
 
 
 
Chemical Data: 
 Formula  : C33H35FN2O5 
 Molecular mass : 558.64g/mol  
Physico chemical properties: 
Atorvastatin is a hydrophobic compound, administered in the open 
ring form. It contains a mevalonic acid like moiety in its structure which 
is responsible for inhibition of the enzyme HMG CoA reductase.Its 
chemical structure is as follows 
35 
 
 
 
 
 
 
3D-Ball and Stick model of the Atorvastatin molecule 
36 
 
 
 Mechanism of action
30
: 
 The rate limiting step in hepatic cholesterol biosynthesis is  the 
reduction of 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate 
which is catalyzed by HMG-CoA reductase. Inhibition of this enzyme 
reduces denovo cholesterol synthesis and  increases the expression of low 
density lipoprotein receptors on hepatocytes. This results in increased 
LDL uptake in the hepatocytes and reduction in LDL levels in blood. In 
addition atorvastatin also causes reduction in triglyceride  levels and 
slight rise in HDL levels. 
 
Pleiotrophic effects of Statins: 
37 
 
Mevalonate, the product of  HMG -  CoA reductase  reaction, is the 
precursor of cholesterol and also  many other nonsteroidal isoprenoidic 
compounds. Hence inhibition of this key enzyme may result in 
pleiotropic effects
30
. 
 
The term statin pleiotrophy encompasses the non LDL mediated 
effects of statin treatment.
31 
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Currently believed nonlipid-related pharmacological properties of statins 
include: 
 Halting of atherosclerosis by the inhibition of macrophage and 
smooth muscle growth and plaque stabilization (ACS implications) 
 Increased post transcriptional endothelial nitric oxide (NO) 
synthase expression and bioavailability (cardiovascular and 
cerebrovascular implications), an ability to recruit endothelial 
progenitor cells (important in repair of ischemic injury), decreased 
endothelin-1 expression, and improved endothelial dysfunction 
secondary to injury (implications in ACS, diabetes) 
 Direct and indirect antioxidant effects, decreased reactive oxygen 
species 
 Improved thrombogenic profile, enhanced expression of tissue 
plasminogen activator and platelet activator inhibitor-1 
 Anti-inflammatory effects; reduction of inflammatory cytokines, 
chemokines, adhesion molecules, and C-reactive protein (CRP) 
molecules , inhibition of a variety of signaling proteins 
(implications in the treatment of bacterial infections, sepsis) 
 Inhibition of lymphocyte growth and other blood mononuclear 
cells (implications for leukemia) 
39 
 
 Immunosuppressive activity, linked to inhibition on promoter IV of 
major-histocompatibility class II (MHC-II) transactivating factor, 
leading to suppression of T-lymphocyte activation (implications of 
statins as immunomodulators and applicability in organ transplant) 
 Inhibition of cardiac hypertrophy, using rat animal models, in vivo 
cardiac hypertrophy induced by angiotensin II infusion (simulating 
HTN) or by transaortic constriction was inhibited by simvastatin 
administration over four weeks 
Other beneficial effects of statins: 
 Mevalonate plays a key role in cell proliferation and thus selective 
inhibition of HMG Co A reductase can lead to a new chemotherapy 
for cancer disease. 
 Recent experiments have shown that mevalonate pathway plays an 
important role in murine and osteoclast formation and bone 
resorption. Subjects with hyperlipidemia with increased risk of 
osteoporosis could benefit from statin therapy. 
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Pharmacokinetics 
Absorbtion 
Atorvastatin undergoes rapid absorbtion when taken orally  and 
peak plasma level occurs at 2.5 hrs. Bioavailability of atorvastatin is 12% 
and their hepatic metabolites varies between 5% and 30% of administered 
doses. 
Distribution 
  In the plasma, >95% of Atorvastatin and their metabolites are 
protein bound.  
Metabolism 
Atorvastatin is extensively metabolized by cytochrome P450, 
CYP3A4 hydroxylation to form active ortho and para hydroxylated  
metabolites which accounts for about 70% of the circulating HMG CoA 
reductase inhibitory activity. 
Excretion 
Atorvastatin and its metabolites are eliminated primarily in bile 
following  hepatic or extra hepatic metabolism. There is no enterohepatic 
circulation. Less than 2% of a dose of Atorvastatin is recovered in urine 
following oral administration. 
41 
 
Uses 
 Primary and secondary dyslipidemias 
 Primary prevention of cardiovascular events according to ATP III 
guidelines 
 Secondary prevention of  myocardial infarction, stroke & unstable 
angina in patients with established coronary heart disease 
 Myocardial infarction and stroke prevention in type II Diabetes 
Mellitus 
Dosage forms 
Available as 10mg, 20 mg, 40 mg tablets and in combination with 
other lipid lowering drugs. 
Untoward effects 
Major  
1. Severe myopathy and rhabdomyolysis are rare (<1%) but life 
thereatening side effects. Severe myopathy can usually be avoided 
by careful patient selection, avoidance of interacting drugs and by 
instructing the patient to contact the physician immediately in the 
event of unexplained muscle pain.  
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In the event of muscle symptoms, the plasma creatine kinase (CK) 
level should be obtained to document the myopathy. Serum CK levels 
need not be monitored on a routine basis in patients taking statins and an 
elevated CK in the absence of symptoms does not predict the 
development of myopathy and does not necessarily suggest the need for 
discontinuing the drug. 
 The risk of statin-associated myopathy is increased in older age, frailty, 
renal insufficiency and by coadministration of drugs that interfere with 
the metabolism of statins such as erythromycin and related antibiotics, 
antifungal agents, immunosuppressive drugs, and fibric acid derivatives 
(particularly gemfibrozil). 
2. Elevation in liver transaminases [alanine (ALT) and aspartate 
(AST)] may also occur (<1%) with therapy. 
Liver enzymes should be checked before starting therapy, at 2–3 
months, and then annually. Substantial (greater than three times the upper 
limit of normal) elevation in transaminases is relatively rare and mild-to-
moderate (one to three times normal) elevation in transaminases in the 
absence of symptoms need not mandate discontinuing the medication. 
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 Severe clinical hepatitis associated with statins is exceedingly rare, 
and the trend is toward less frequent monitoring of transaminases in 
patients taking statins. The statin-associated elevation in liver enzymes 
resolves upon discontinuation of the medication. 
Other common side effects include 
 Dyspepsia, 
 Headaches,  
 Fatigue, and  
 Muscle or joint pains.  
Drug interactions 
Inhibition by other drugs of OATP1B1, which transports several 
statins into hepatocytes, and inhibition or induction of CYP3A4 by a 
variety of pharmacological agents provide rationales for drug-drug 
interactions involving statins 
Most commonly statin interacts with  
 fibrates, especially gemfibrozil (38%),  
 cyclosporine (4%),  
 digoxin (5%), 
  warfarin (4%), 
  macrolide antibiotics (3%),  
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 mibefradil (2%), and 
  azole antifungals (1%) . 
 Other drugs that increase the risk of statin-induced myopathy 
include niacin,  HIV protease inhibitors, amiodarone, and nefazodone . 
Use in specific populations: 
Geriatric Use 
 
Atorvastatin metabolism appears to be slower in the elderly 
resulting in greater bioavailability and longer half life, however no dose 
adjustment is necessary. 
Renal Dysfunction 
Kidney plays no role in the disposition of atorvastatin, dosage 
adjustment in patients with renal impairment is not necessary. 
Hepatic impairment 
Patients with hepatic disease may not be able to clear the drug 
effectively, hence atorvastatin is contraindicated in active liver disease.  
 
 
 
45 
 
BIOTIN 
Synonyms:  
 Vitamin H, Coenzyme R, Vitamin B7. 
 Biotin is a water soluble B - complex vitamin discovered 
around 70 years ago. Other name of biotin is vitamin H, the H 
representing “Haar and Haut”, which means “hair and skin” in German. It 
was originally identified as  a growth factor in yeast.
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Chemical structure: 
 Chemically Biotin is cis-tetra hydro-2-oxothienol[3,4-d]-
imidazoline-4-valeric acid. It consists of a tetrahydrothiophene ring fused 
with  an ureido (tetra hydro imidizalone )ring. The ureido ring and the 
ionizable carboxyl group of biotin allow modest solubility of the white 
crystalline solid in aqueous solution, especially  at an alkaline pH. Its 
chemical structure is as follows.
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3D BALL AND STICK MODEL OF BIOTIN 
 
Dietary sources:         
Biotin  cannot be synthesized  as such by  humans and mammals 
and has  be obtained  from diet or synthesised by intestinal bacteria. 
Good sources of biotin  are  
 seafood, red meat, liver, pork and beef. 
 Egg yolks,milk,curd. 
 Cauliflower, lettuce, cucumber and spinach. 
 Fruits like banana, avocado, cranberries, 
strawberries,raspberries. 
 Soy products, peanut. 
  Cashews, almonds, walnuts and sunflower seeds. 
 Cereal grains , fruits , most vegetables and meat are poor sources . 
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SOURCES OF BIOTIN 
 
Absorbtion , Transport , Metabolism and Excretion
33
: 
          Biotin in the diet is largely protein bound and digestion of these 
proteins by gastrointestinal enzymes produces biotinyl peptides, which 
may be further hydrolysed by intestinal biotinidase to release biotin. 
          Avidin, a protein found in raw egg whites, binds biotin tightly and 
prevents its absorbtion. The peptide biocytin (€-N-bitoinyl lysine) is 
resistant  to hydrolysis by proteolytic enzymes in the intestinal tract but 
together with Biotin is readily absorbed. 
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           A Biotin carrier, the sodium dependant multivitamin transporter 
(SMVT) for which pantothenic acid and lipoate compete is present  in the 
brush border  membrane of intestines. This helps in the  transport of  
biotin against a sodium ion concentration gradient. The enzyme 
biocytinase (biotin amidohydrolase) in plasma and erythrocyte catalyzes 
the hydrolysis of  biocytin to yield free biotin. The clearance of Biotin is  
more rapid in deficient individuals. During circulation the free biotin  is 
taken up by  liver, kidney and muscle and is localized in cytosolic and 
mitochondrial carboxylases. About half of the absorbed biotin is excreted 
as the metabolite bisnorbitin, occurring from β-oxidation of the valeric 
side chain, and biotin sulfoxide. The urinary excretion and fecal excretion 
of biotin exceeds dietary intake  because of microfloral biosynthesis. 
  Bioavailability:  
The bioavailability of biotin is variable. In general it is seen  in 
food in the  proteinbound form called biocytin. This bound form should 
undergo proteolysis prior to absorbtion. In egg whites biotin is bound 
tightly to avidin which   prevents its intestinal absorbtion, when 
consumed raw. Cooking denatures the avidin thereby assisting  free biotin 
release and  facilitating  biotin absorbtion. Oxidising agents convert the 
thioether to sulfoxides and sulfones which donot have biotin activity. 
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Physiological roles: 
Biotin is an essential co-factor for carboxylase enzymes in many 
biochemical pathways. It acquires a carboxyl substituent in its ureido 
group and thus functions as CO2 carries in these reactions. Thus it is 
essential for cell growth  and an important requisite in the synthesis of 
fatty acids and plays a major role in the metabolism of fats and amino 
acids.
 
Studies have proven that biotin regulates gene expression in 
addition to  its role as carboxylase prosthetic group. Biotin has shown to 
stimulate  genes favouring hypoglycemia like the genes coding for 
insulin, insulin receptor and  glucokinase. It also decreases the expression 
of phosphoenolpyruvate carboxykinase in the liver. PEPCK is the key 
enzyme of gluconeogenesis. It helps in  glucose production by the liver.
 
These findings indicate that biotin is an important vitamin involved in 
glucose and lipid metabolism. Few studies have proved that  biotin 
deficiency is associated with  decreased utilization of glucose 
and.impaired glucose tolerance.
34
 Few more studies have shown that 
pharmacological doses of biotin are effective in diabetes mellitus. 
Another study conducted in a smaller number of subjects have 
shown that  61.4 micromol /day of biotin significantly reduced the plasma 
triglyceride level and VLDL levels.
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Other applications: 
 Biotinylation is the process of attachment of the vitamin to 
different chemical sites. This is utilized  in  various  laboratory techniques 
in biochemistry. In the   study of  DNA transcription, DNA replication, 
protein localization and protein interactions, biotin is now being used. 
The property of  binding  very tightly to  avidin  is also used in different 
biotechnological applications. 
Deficiency: 
Biotin deficiency in human beings is a rare occurrence as it is seen 
in many foods and easily synthesized by intestinal bacteria. It may be 
seen in  severe malnutrition or inborn errors of metabolism like  
biotinidase deficiency , multiple carboxylase deficiency. Consumption of 
large quantities of raw egg whites may also cause biotin deficiency.  
 Low levels of biotin are also seen in  those who have undergone 
partial gastrectomy and in patients with  burns, epilepsy, atheletes and old 
age. Marginal biotin deficiency may occur in pregnancy and lactation. 
The common deficiency symptoms are nausea, vomiting, anorexia, 
glossitis, depression, pallor and a dry scaly dermatitis. Symptoms of 
severe deficiency include erythematous skin lesions, hypotonia and 
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ataxia. Children with biotin deficiency present with vomiting, seizures & 
developmental delay. 
Requirements
35
: 
•For Men  :  30 micrograms/day 
•For Women :  30 micrograms/day 
•For Pregnancy :  30 micrograms/day 
•For Lactation :  35 micrograms/day 
Toxicity: 
 In patients with biotinidase deficiency administration of doses 
even upto 300 times  normal dietary intake was not associated with any 
adverse events 
36
. 
Laboratory assessment of status: 
Biotin is measured in biological samples by microbiological assay, 
where whole blood is first digested with papain or acid hydrolysis to 
release free biotin , samples of which are added to a biotin –deficient 
medium , inoculated with a test organism. 
Other methods for measuring unbound biotin include avidin 
binding assays, where a competitive protein – binding radio assay is setup 
with H-labelled biotin, and non radioactive enzyme linked sorbent assays, 
using steptavidin as the binding agent. 
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Urinary excretion of biotin and 3-hydroxyvaleric acid appears to be 
a better indicator of biotin status than blood concentrations.
37
  
  The most sensitive indicator of biotin deficiency is  
measurement of Lymphocyte propionyl carboxylase measured by an 
optimized assay. 
Reference intervals: 
Reference interval values for whole blood biotin by a 
microbiological method are 0.5 to 2.20 nmol/l , with a mean of 1.31 
nmol/l.
38
  
Deficiency is considered  likely below 0.5 nmol/l. 
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AIM 
 To  determine  the  plasma  lipid lowering  effect  of  biotin, 
by comparing  the efficacy and side effect profile of the combination 
therapy of Biotin and Atorvastatin with  monotherapy of 
Atorvastatin. 
  
PRIMARY OBJECTIVES 
1. To compare the percentage change from baseline in LDL 
cholesterol  at   
1
st
, 2
nd
, 4
th
 and 6
th   
week  between the two groups - control and 
study group. 
2. To compare the percentage change from base line in other lipid 
parameters at 1
st
,  2
nd
,  4
th
  and 6
th
  week  between the two groups. 
 
SECONDARY OBJECTIVE 
To compare the side effect profile and laboratory parameters 
between the two groups during the treatment. 
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EVALUATION OF THE EFFECT OF BIOTIN IN 
DYSLIPIDEMIA 
 
METHODOLOGY: 
 This  study  was  conducted  among  outpatients  attending  the  
Hypertension  clinic of the  Department  of  Medicine  with  dyslipidemia  
eligible  for  lipid lowering  therapy. 
STUDY DESIGN 
Single centre, prospective, open label, parallel group, comparative  
study conducted  for  a  period  of  12  weeks . 
STUDY CENTRE 
Hypertension  clinic  of  the Department of Medicine, Government 
Stanley Medical College and Hospital, Chennai-1. 
STUDY POPULATION 
Outpatients who visited the hypertension clinic with dyslipidemia 
eligible for lipid  lowering   therapy. 
SAMPLE SIZE 
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60 patients 
 
STUDY PERIOD 
From March 2013 to February 2014 
STUDY DURATION 
12 weeks for each patient 
STUDY DRUGS 
1) Tablet Atorvastatin 10 mg obtained from govt. supply at Stanley 
Hospital. 
2) Tablet Biotin 5 mg  (trade name ESSYVIT, Ranbaxy Pharma)  
purchased from retail outlets.  
         The batch number, date of manufacturing,  bill number from retailer 
,date of purchase were entered in the drug treatment form used for each 
patient. 
SELECTION CRITERIA: 
 Inclusion criteria 
 Age range 45-60 years 
 Both sexes  
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 Newly diagnosed cases of  dyslipidemia with 
 Plasma total Cholesterol > 200 mg/dl 
 Plasma LDL levels = 100-189 mg/dl  
 Plasma triglyceride >150 mg/dl 
 Plasma VLDL >30 mg/dl 
 Plasma HDL <40 mg/dl 
 Diabetes mellitus  (Type 2 ) or hypertension  (systolic 
Bp<160 mm hg and diastolic Bp<100 mm hg)  
 Patients who were willing to give informed consent.  
 
 Exclusion criteria 
 Age less than 45 years or more than 60 years 
 Patients with high plasma levels of LDL cholesterol alone or 
high plasma levels of triglyceride alone. 
 Patients with very high levels of plasma total cholesterol 
(i.e., more than 500 mg/dl) and very high levels of plasma 
triglyceride ( i.e., more than 500 mg/dl) . 
 Patients with uncontrolled Diabetes Mellitus (i.e., Fasting 
Blood Sugar>140 mg/dl). 
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 Patients with uncontrolled hypertension (i.e., systolic BP 
>160 mm hg and diastolic BP >100 mm hg). 
 Patients with history or clinical evidence of  ischaemic heart 
disease or unstable angina or stable angina or 
cerebrovascular disease or peripheral arterial disease or 
neuromuscular disorders. 
 Patient with history or laboratory evidence of liver 
dysfunction. 
 Patient with history or clinical evidence of renal dysfunction. 
 Patient with metabolic or hormonal disorders. 
 History of smoking or alcoholism. 
 History of thyroid dysfunction. 
 Patients who took antiplatelet drugs. 
PROCEDURE: 
 The study was conducted after obtaining approval from the 
Institutional Ethics Committee. Patients with Type 2 Diabetes mellitus or 
Hypertension who visited the Hypertension clinic were explained about 
the study purpose and procedures.  
           A total of 80 patients who were willing to participate in this study 
and willing to give written informed consent were selected for screening. 
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Written informed consent in their own language was obtained from 
the selected patients. 
SCREENING: 
           Screening procedure consisted of a detailed medical and drug 
history, thorough clinical examination followed by laboratory 
investigations – which included fasting lipid profile, liver and renal 
function tests.  
         After screening  20  patients  were  excluded  based  on  selection 
criteria. 
          A  total  of  60  patients  of  both   sexes  and age  between  45  to  
60 years who  fulfilled  the  selection  criteria  were  recruited  for  the  
study. 
RANDOMIZATION: 
          The study subjects were randomly assigned using a computer 
generated randomization chart  to  either of  the  two  groups  Group A 
and Group B,   each group  consisting of 30 patients.     
 STUDY PROCEDURE:       
          Each  patient  was  registered  as  a new  Dyslipidemia  case  and  a  
case  record  form  was  maintained  for  each  patient.  
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DOSAGE REGIMEN 
 
At  the  first  visit  tablets  were  given  for  one  week  according  
to  the  above  dosage  regimen. 
              Patients  were  advised  to  continue  their  antihypertensive  or 
antidiabetic  medication  as  before.  No  special  diet  instruction  was  
given. 
           Participants  were  instructed  to  come  in  between  if  any  
myalgia  or  any  other  adverse  event  occurred. 
           All  patients  were  reviewed  at  the  end  of  1
st
, 2
nd
, 4
th
 and  6
th
  
week.  At  each visit  fasting  lipid  profile   was  done  and   plasma  lipid  
levels  were  noted  and adverse  event  monitoring  was  also  done 
through out the study period. 
            After   treatment  period  of  6  weeks  the   study  medications  
were  stopped  and  participants  were  referred  back  to  their  respective  
Group A T.Atorvastatin 20 mg  daily  after dinner for 6 weeks 
Group B T.Biotin 5 mg +T.Atorvastatin 20 mg  daily  after dinner 
for 6 weeks. 
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departments  and received Atorvastatin 20 mg daily at bedtime for 6 more 
weeks.  The study participants were followed up till the 12
th
 week. All  
investigations including plasma lipid profile were  repeated at the end of 
12
th
 week. 
INVESTIGATIONS 
HEMATOLOGICAL 
 Complete hemogram  
 Hemoglobin percentage  
 Total count 
 Differential count 
 Erythrocyte sedimentation rate 
 Platelet count 
BIOCHEMICAL 
 Fasting Plasma lipid profile 
 Total Cholesterol 
 LDL 
 Triglycerides 
 VLDL 
 HDL 
 Liver function tests 
 SGOT,SGPT 
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 Renal function tests 
 Blood urea 
 Serum creatinine 
 Creatinine phosphokinase  
OUTCOME  MEASURES 
The   primary   efficacy   measure   was  the  percentage   reduction   
in   the   plasma   lipid   after   the   6   weeks   of   treatment. 
Safety   evaluation   was   based   on   the   spontaneously   reported   
adverse   events   and   the   changes  in   the   liver   function   tests   and 
laboratory   values   after   the   study. 
STATISTICAL ANALYSIS: 
Data   was   expressed   as   mean  ±  standard  deviation. Students   
independant „ t‟   test   was   used   for   comparing   quantitative   data   
between   the   two   groups. At   the   end   of   the   study   the   effects   
of   Atorvastatin   alone   and combination   of   Atorvastatin   with   
biotin  on   lipid   profile   was  compared    in   terms   of   therapeutic    
efficacy  and  adverse   effects. 
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(80) 
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INCLUDED(60) EXCLUDED(20) 
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RESULTS 
 A total of 80 dyslipidemic patients  were selected and screened 
for the study. Based on the selection criteria, 20 patients were excluded 
GROUP A(30 patients) 
AT0RVASTATIN 20 mg 
for 6 weeks at bed time 
 
 
GROUP B(30 patients) 
ATORVASTATIN20mg+ 
BIOTIN 5 mg for 6 weeks 
at bed time  
 
REVIEW AT end of 1, 2, 4 and 6 WEEKS  
FOLLOW UP AT end of 12 WEEKS 
DATA COMPILATION AND ANALYSIS 
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and the remaining 60 patients  were  randomly allocated into two groups 
of 30 patients each.There were no dropouts in each of the groups. 
 Baseline characteristics of both the groups including the mean 
age, sex distribution, associated diseases like diabetes mellitus, 
hypertension and baseline lipid profile were assessed and tabulated. 
 Plasma lipid profile was repeated at 1
st
,  2
nd
,  4
th
  and 6
th
  week 
of treatment and the percentage change in each of the plasma lipoproteins 
from baseline was calculated and statistically analysed by students 
independent „t‟ test. 
After 6 weeks of treatment, Biotin was stopped and both the study 
and control groups  received  mono therapy with  Atorvastatin in their 
respective departments for the next 6 weeks . 
Plasma lipid profile and laboratory parameters of both the groups 
was repeated at the end of 12 weeks to find out any delayed effects of 
Biotin.  
Adverse event monitoring was done for the 12 weeks of study 
period and the adverse events and the additional observed effects were 
noted and tabulated. 
TABLE no. 1: BASELINE CHARACTERISTICS OF THE  TWO 
GROUPS 
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BASELINE 
CHARACTERISTICS 
CONTROL 
GROUP(30) 
MEAN 
STUDY 
GROUP(30) 
MEAN 
1. Mean age in yrs 50.70 50.13 
2. Number of males    (%) 
3. Number of females (%) 
13(43.3) 
17(57.7) 
13(43.3) 
17(57.7) 
4. Diabetes Mellitus    (%) 7(23.3) 8(26.6) 
5. Hypertension           (%) 28(93.3) 27(90) 
BASELINE LIPIDS   
6. Total Cholesterol        
(mg/dl) 
263.76 286.73 
7. LDL Cholesterol         
(mg/dl) 
158.06 173.76 
8. Triglyceride                
(mg/dl) 
170.03 210.6 
9. VLDL Cholesterol      
(mg/dl) 
36.33 41 
10. HDL Cholesterol        
(mg/dl) 
46..44 47.33 
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Table no. 1 shows 
 The baseline demographic characteristics and lipid profile of both 
the groups. 
 The incidence of diabetes mellitus was similar in both the groups. 
Diabetes mellitus was present in 23.3% of the subjects in the 
control group  vs.  26.6%  of the subjects in the study group. 
  The incidence of hypertension was similar in both the groups. 
Hypertension was present in   93.3% of the subjects in the control 
group vs. 90% of the subjects in the study group. 
 The baseline lipid parameters were 
o The mean total cholesterol of the control group - 263.76mg/dl 
vs. 286.73 mg/dl in study group.  
o The mean LDL of the control group - 158.06 mg/dl vs. 173.76 
mg/dl in study group.  
o The mean triglycerides of the control group - 170 mg/dl vs. 210 
mg/dl in the study group.  
o The mean VLDL of the control group - 36.33 mg/dl vs.41 
mg/dl in the study group.  
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o Mean HDL of the control group - 46.44 mg/dl vs.47.33 mg/dl 
in the study group. 
 
TABLE NO 2 : MEAN AGE OF BOTH GROUPS 
  
 
Group 
 
N Mean 
Standard. 
Deviation 
Student’s 
independent 
‘t’ –test 
 
 
Age(yrs) 
  
 
Control 
 
30 
 
50.70 
 
3.131 
„t‟ = 0.682 
„p‟= 0.498 
Not 
significant 
 
Study 
 
30 
 
50.13 
 
3.298 
 
** p ≤ 0.010 it implies Highly Significant, * p ≤ 0. 050 it implies Significant,  p > 
0.050 it implies Not Significant 
 
 
 
FIGURE no: 1    MEAN AGE OF THE TWO GROUPS 
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Table no 2 shows 
 The comparison of the mean age of the study participants of the 
two groups - control and study groups. 
 The mean age of patients in the control group was 50.7 yrs  vs. 
50.13 yrs in study group. 
 Statistical analysis was done by using student‟s independent „t‟ 
test and „p‟ value was not significant p=0.498. 
 There was no significant difference in mean age between two 
groups  
45
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Figure no 1 is a graphical representation of  the data in table no 1. 
 It is a bar graph showing  the comparison of mean age of 
patients in both the groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE NO 3 : COMPARISON OF AGE DISTRIBUTION 
 
 
AGE  
INTERVAL 
 
CONTROL (30) 
 
 
TEST (30) 
 
NO 
 
% 
 
NO 
 
% 
 
45-49yrs 
 
 
11 
 
 
36.66 
 
 
12 
 
 
40 
 
 
50-54yrs 
 
17 
 
 
56.66 
 
 
17 
 
 
56.66 
 
 
>55 yrs 
 
2 
 
6.66 
 
1 
 
3.33 
 
TOTAL 
    
70 
 
 
FIGURE NO 2 
 
 
 
Table no. 3 shows 
 The age distribution of patients of the control and study groups.. 
 In the control group 11(36.6%) patients were in 45-49 yrs age 
interval vs. 12 (40%) patients in the study group. 
 In both the control and study group 17(56.6%) were in the 50-54 
yrs age interval. 
 In the control group 2(6.66%) patients were in the 55-60 yr age 
group vs. 1(3.33%) patient in study group. 
0
5
10
15
20
45-49yrs 50-54yrs >55yrs
11 
17 
2 
12 
17 
1 
Number of  
patients 
Age interval 
Comparison of Age Distribution 
Control
Study
30 100 30 100 
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 Both the study and control groups had comparable age distribution. 
 There were more  patients in the 50-54 yr age interval. 
Figure no.2 is a graphical representation of the data of table no.3.It is a 
bar graph showing the comparison of age distribution of patients in both 
the groups. 
 
 
 
 
 
 
 
TABLE no 3:  GENDER DISTRIBUTION 
 
 
 
GROUP 
 
PEARSON CHI-
SQUARE TEST 
Control Study 
Number % Number % 
 
Male 
Female 
 
13 
17 
 
43.3% 
56.7% 
 
13 
17 
 
43.3% 
56.7% 
 
χ2=0.00 
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Total 
 
30 
 
100 
 
30 
 
100 
 
FIGURE no 3: COMPARISON OF GENDER DISTRIBUTION 
 
              
 
 
 
 
Table no 3 shows 
 The gender distribution of patients in both the groups. 
 The ratio of male to female in both the groups is13:17.  
13 
17 
Control group 
Male
Female
13 
17 
Study group 
Male
Female
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 Statistical analysis was done by using χ 2 test and the p value was 
not significant.  
 There was a female preponderance in both the groups. 
 There was no significant difference in the gender distribution 
between the two groups. 
Figure no 3 is a graphical representation of the data of Table no 3.The 
gender distribution of the control and study groups are represented as a 
pie chart. 
 
 
 
 
 
 
 
Table no 4a : Comparison of  mean total cholesterol levels in both the 
groups  
 Control Study 
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Mean TC level 
(mg/dl) 
% redn Mean TC level 
(mg/dl) 
% redn 
Baseline 263.76 - 286.73 - 
1
st
 week 221.00 16.7% 240.4 16.06% 
2
nd
 week 194.00 26.32% 186.2 34.66% 
4
th
 week 189.00 28.33% 167.46 41.33% 
6
th
 week 188.00 28.68% 169.8 40.37% 
12
th
 week 191.00 27.56% 208.3 29.96% 
 
Table no 4b: Comparison of % reduction from Baseline in Total 
Cholesterol between two groups 
 Control(% redn) Study(% redn)  
‘p’ value  Mean SD Mean SD 
Baseline - - - -  
1
st
week 16.7% 5.6 16.06% 4.37 0.623 
2
nd 
week 26.32% 4.4 34.66% 8.52 0.000**
 
4
th 
week 28.33% 5.05 41.33% 7.74 0.000** 
6
th
week 28.68% 5.56 40.37% 9.91 0.000** 
12
th
week 27.56% 5.7 26.96% 5.02 0.671 
 
** p ≤ 0.010 it implies (Highly Significant ), * p ≤ 0. 050 it implies (Significant) , p > 
0.050 it implies Not Significant 
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Figure no 4: Comparison of % change in Total Cholesterol between two groups 
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Table no 4a shows 
 The mean total cholesterol levels in both the groups and the 
percentage reduction from the baseline at 1
st
, 2
nd
, 4
th
, 6
th
 &12
th
 
week. 
Table no 4b shows 
 The mean and standard deviation of the percentage reduction in 
total cholesterol levels. Statistical analysis was done by using 
students independent „t‟ test.  
 By the first week of study there was16.7% reduction in total 
cholesterol in control group vs 16.06% in study group, but this 
difference was not statistically significant p=0.623. 
 By  second week of study there was 26.32%  reduction in total 
cholesterol in the  control group  vs  34.66%  reduction in the 
study group,  the difference in the reduction percentages was 
highly significant statistically (p=0.000**).  
 At fourth week of study there was 28.33% reduction  in total 
cholesterol in the control group vs 41.33% reduction in the total 
cholesterol in the study group. On statistical analysis the difference 
in percentage reduction was found to be significant (p=0.000**). 
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 At six weeks, there was 28.68% reduction in total cholesterol in 
the control group vs.40.37% reduction in the study group. On 
statistical analysis the difference in percentage reduction was found 
to be statistically highly significant (p=0.000**). 
 At the follow up 12th week, there was 27.56% reduction in total 
cholesterol in the control group vs 26.96% reduction in total 
cholesterol in the study group. On analysis this difference was not 
statistically significant (p=0.671). 
Figure no 4 is the column chart  representing  the data in table no 4b. 
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Table 5a: Comparison of the mean LDL levels in both the groups  
 Control Study 
mean LDL level 
mg/dl 
% redn mean LDL level 
mg/dl 
% redn 
Baseline 158 - 173 - 
1
st
 week 127 19.08% 147 16.90% 
2
nd
 week 103 34.35% 104 39.89% 
4
th
 week 100 35.89% 89 42.62% 
6
th
 week 99 36.95% 90 43.28% 
12
th
 week 101 35.12% 104 36.57% 
 
Table no 5b: Comparison of % reduction from Baseline in LDL 
levels between two groups 
 Control(% redn) Study(% redn) ‘p’ value 
 Mean SD Mean SD  
Baseline - - - -  
1
st
week 19.087% 4.14 16.90% 4.04 0.044* 
2
nd 
week 34.35% 1.77 39.89% 6.24 0.000**
 
4
th 
week 35.89% 6.65 42.62% 5.65 0.000** 
6
th
week 36.95% 3.92 43.28% 5.007 0.000** 
12
th
week 35.12% 4.37 36.57% 4.51 0.544** 
 
** p ≤ 0.010 it implies Highly Significant, * p ≤ 0. 050 it implies Significant, 
p > 0.050 it implies Not Significant 
 
79 
 
Figure no 5:Comparison of % reduction from Baseline in LDL Cholesterol between two groups 
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Table no 5a shows 
 The mean LDL cholesterol levels of the study and control  groups 
and the percentage reduction in LDL cholesterol from baseline at 
1
st
 , 2
nd
 , 4
th
 , 6
th
  &12
th
  week.  
Table no 5b shows 
 The mean and standard deviation of the percentage reduction in 
LDL levels. Statistical analysis was done by using students 
independent „t‟ test. 
 By the first week, there was a 19.08% reduction in LDL 
cholesterol levels from baseline in the  control group vs. 16.90 % 
reduction from baseline in the study group. This difference was 
statistically significant (p=0.044*). 
 At the second week, there was a 39.89% reduction in LDL 
cholesterol levels from baseline in the study group vs. 34.35% 
reduction in LDL cholesterol levels from baseline in the control 
group. On statistical analysis, this difference was statistically 
highly significant (p=0.000**). 
 At the fourth week, the study group showed a 42.62% reduction in 
LDL cholesterol levels from baseline vs. 35.89% reduction from 
81 
 
baseline  in the control group. This difference was found to be 
highly significant on statistical analysis (p=0.000**). 
 At the sixth week, the study group showed a 43.28% reduction in 
LDL cholesterol vs. 36.95% reduction  in control group and this 
difference was statistically highly significant (p=0.000**). 
 At the twelfth week there was no statistically significant difference 
in the percentage reduction in LDL cholesterol levels. The % 
reduction in LDL cholesterol in the control group was 35.12% vs 
36.57% in the study group (p=0.544). 
Figure 5 is a column chart representing the percentage reduction from 
baseline in LDL levels in the control and study groups at 0,1st, 2nd, 4th, 
6th&12th week. 
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Table 4a: Mean Triglyceride levels in both the groups  
 Control Study 
Mean TG 
mg/dl 
% redn Mean TG 
mg/dl 
%redn 
Baseline 170 - 210.6 - 
1
st
 week 160.5 5.66 179.6 13.96 
2
nd
 week 138.7 18.34 155.03 25.92 
4
th
 week 136.63 19.88 155.4 25.65 
6
th
 week 136.36 20.66 147.26 28.45 
12
th
 week 135.5 19.36 165.23 20.69 
 
Table no 6b: Comparison of % reduction from Baseline in 
Triglyceride levels between two groups 
 Control(% redn) Study(% redn) ‘p’ value 
 Mean SD Mean SD  
Baseline - - - -  
1
st
week 5.66% 2.79 13.96% 5.74 0.000** 
2
nd 
week 18.34% 1.26 25.92% 9.60 0.000**
 
4
th 
week 19.88% 3.61 25.65% 8.55 0.002** 
6
th
week 20.66% 9.26 28.45% 8.93 0.002* 
12
th
week 19.36% 9.41 20.69% 8.86 0.577 
 
** p ≤ 0.010 it implies (Highly Significant), * p ≤ 0. 050 it implies 
(Significant) , p > 0.050 it implies Not Significant 
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Figure no 6 : Comparison of % reduction from Baseline in Triglyceride levels between two groups 
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Table no 6a shows 
o The mean triglyceride levels and the percentage reduction from 
baseline  in both the groups at 1
st
 , 2
nd
 , 4
th
 ,6
th
 & 12
th
  week. 
Table no 6b shows 
 The mean and standard deviation of the   percentage reduction in 
triglycerides. Statistical analysis was done by using students 
independent „t‟ test. 
 By the end of the first week, the control group had 5.66% 
reduction in triglycerides vs 13.96% reduction in the study group. 
The difference in percentage reduction between two groups was 
statistically highly significant (p=0.000**). 
 By the end of the second week, there was greater percentage 
reduction in triglyceride levels in the study group when compared 
to the control group. The percentage reduction in study group was 
25.92% when compared to the control group which had 18.34% 
reduction. The difference between the  two groups was statistically 
highly significant (p=0.000**). 
 At the end of the fourth week the control group had 19.88% 
reduction vs 25.65% reduction  in the study group. The  
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difference between two groups  was  statistically highly significant 
(p = 0.002**). 
 At the sixth week the control group had 20.66% reduction vs 
28.45% reduction  in the study group.On statistical analysis the 
difference between two groups was statistically highly significant 
(p=0.002). 
 At the end of the twelfth week, there was no significant difference 
in percentage reduction in triglyceride levels between the two 
groups (p=0.422). The percentage reduction in triglyceride levels 
was 19.36% in the control group vs 20.69% in the study group. 
Figure no 6 is a column chart representing the percentage reduction in 
triglyceride levels from baseline at 1
st
, 2
nd
, 4
th
, 6
th
 &12
th
 week of the 
study. 
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Table 7a: Comparison of the VLDL levels in both the groups  
 Control Study 
Mean 
VLDL 
mg/dl 
% redn Mean 
VLDL 
mg/dl 
% redn 
Baseline 36.33 - 41 - 
1
st
 week 34.66 4.75% 39.23 6.2% 
2
nd
 week 27.9 23.05% 27.93 30.3% 
4
th
 week 24.56 32.03% 26.36 33% 
6
th
 week 23.36 36.16% 26 35.4% 
12
th
 week 23.63 34.56% 30.16 27.8% 
 
Table no 7b: Comparison of % reduction from Baseline in 
VLDL levels between two groups 
 Control(% redn) Study(% redn) ‘p’ value 
 Mean SD Mean SD  
Baseline - - - -  
1
st
week 4.75% 3.88 6.2% 6.36 0.292 
2
nd 
week 23.05% 16.81 30.3% 15.11 0.084 
4
th 
week 32.03% 14.38 33% 15.38 0.655 
6
th
week 36.16% 12.26 35.4% 16.12 0.839 
12
th
week 34.56% 14.58 27.8% 19.51 0.134 
 
** p ≤ 0.010 it implies Highly Significant, * p ≤ 0. 050 it implies Significant , p > 
0.050 it implies Not Significant 
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Figure no 7: Comparison of % reduction from Baseline in VLDL levels between two groups 
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Table no 7a shows 
 The mean VLDL levels and percentage reduction in VLDL 
levels from baseline of the control and study groups at 0,1
st
 ,2
nd
 ,4
th
 ,6
th
 
&12
th
  week. 
Table no 7b shows 
 The mean and standard deviation of  the  percentage reduction  in 
VLDL in  both  groups. Statistical analysis was done by using 
students independent „t‟ test. 
 At  the end of the first week, the study group had 6.2% reduction 
in VLDL levels vs 4.75% reduction in control group, this 
difference was not statistically significant ( p=0.292).   
 At the end of the second week, the study group had 30.3% 
reduction in VLDL levels vs 23.05% in  control group, but this 
difference was  not statistically  significant (p=0.084). 
 At the end of the fourth week, the study group had 33% reduction 
in VLDL levels vs 32.03% in  the control group, but this 
difference was not statistically significant (p-0.655).  
 At  the end of the sixth week,  the study group had 35.4% 
reduction percentage in VLDL  level vs 36.16% in control group. 
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On statistical analysis this difference was not statistically 
significant (p = 0.839). 
 At the end of the  twelfth week,  there was 35.46% reduction in 
VLDL levels vs 27.8% reduction in the study group, this 
difference was not statistically significant (p=0.134). 
Figure no 6 is a column chart showing the percentage reduction in 
VLDL levels of the study and control groups at 0,1
st
 ,2
nd
 ,4
th
 ,6
th
 &12
th
  
week of the study. 
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Table 8a: Mean HDL levels in both the groups  
 Control Study 
Mean   
HDL mg/dl 
% change Mean HDL 
mg/dl 
% change 
Baseline 46.44 - 47.3 - 
1
st
 week 45.6 -1.26 46.22 -2.29% 
2
nd
 week 46 -0.25 47.17 -0.35% 
4
th
 week 46.26 -0.11  48.39 2.32% 
6
th
 week 47.5 2.83 47.9 4.17% 
12
th
 week 48.76 6.11 47.66 3.47% 
 
Table no 8b:Comparison of % change from Baseline in HDL 
levels between two groups 
 Control(% change) Study(% change) ‘p’ value 
 Mean SD Mean SD  
Baseline - - - -  
1
st
week -1.26% 6.54 -2.29% 2.95 0.09 
2
nd 
week -0.25% 8.01 -0.35% 7.36 0.620 
4
th 
week -0.11% 5.60 2.32% 7.23 0.150 
6
th
week 2.83% 6.84 4.17% 9.01 0.518 
12
th
week 6.113% 8.80 3.47% 4.09 0.142 
 
** p ≤ 0.010 it implies (Highly Significant), * p ≤ 0. 050 it implies  (Significant) , p > 
0.050 it implies Not Significant 
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Figure  no 8: Comparison of % reduction from Baseline in HDL levels between two groups
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Table no 8a shows 
 The mean HDL levels and the percentage change  from base line at 0, 
1
st
 , 2
nd
 , 4
th
 , 6
th
 & 12
th
  week in both the groups. 
Table no 8b shows 
 The comparison of percentage change from baseline in HDL  in  both  
groups, statistical analysis was done by using students t test.  
 By the end of the  first week, there was  a 1.26% reduction in HDL levels in 
control group  vs  2.2% reduction in study group, this difference was not  
statistically   significant (p=0.09). 
 By  the end of the second week.  the control group had a 0.25% fall in HDL 
levels vs 0.35%  fall  in study group, this difference was not statistically 
significant (p=0.620). 
 At the end of the  fourth week, the control group had a 0.11% reduction in 
HDL levels vs2.32% rise in study group. On statistical analysis  this 
difference was not statistically significant (p=0.150).   
 At the end of the sixth week, the control group had 2.83% rise in  HDL level 
vs 4.17% rise in the study group but the  difference was not  statistically 
significant   (p = 0.518). 
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 At the end of the  twelfth week, the control group had 6.11% rise in HDL 
levels vs 3.47% rise in the study group, but the difference was not 
statistically significant (p=0.142).  
Figure no 8 is a column chart showing the percentage change in HDL levels 
from base line at 0,1
st
, 2
nd
, 4
th
, 6
th
 &12
th
  week of both the groups. 
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Table no 9: Comparison of Total cholesterol: HDL-cholesterol ratio 
between study and control groups 
 Mean total CH:HDL CH ratio 
Control  group Study group 
Baseline 5.68 6.06 
1
st
 week 4.84 5.09 
2
nd
 week 4.21 3.84 
4
th
 week 4.08 3.46 
6
th
 week 3.95 3.54 
12
th
 week 3.91 4.36 
 
Figure no 9 :Comparison of the total: HDL ratio of both the groups 
 
5.68 
4.84 
4.21 4.08 
3.95 
3.91 
6.06 
5.09 
3.84 3.46 3.54 
4.36 
Baseline 1st week 2nd week 4th week 6th week 12th week
STUDY DURATION IN WEEKS 
Total cholesterol : HDL ratio 
Study group
Control  group
95 
 
Table no 9 shows  
 The ratio of  total cholesterol and HDL cholesterol in both the groups  
during the study. 
 In the control group the total cholesterol : HDL cholesterol ratio was 5.68 
at baseline, thereafter it reduced to 4.84 at 1
st
 week, 4.21 at 2
nd
 week, 4.08 
at 4
th
 week, 3.95 at 6
th
 week and 3.91 at 12
th
 week.  
 In the study group the total cholesterol: HDL cholesterol ratio was 6.06 at 
baseline, later it reduced to 5.09 at 1
st
 week and 3.84 at 2
nd
 week. From 
the 4
nd
 week onwards the ratio was in the desirable level of ≤3.5. 
 After the discontinuation of  study drug, the ratio became 4.36 in the 
study group. 
Figure no 9 is a line diagram representing the data of the table no 9. 
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TABLE no 10: BASIC  HEMATOLOGICAL  INVESTIGATIONS   BEFORE 
AND AFTER THE STUDY 
 
Parameter  Group  Baseline value End of study Student  
paired 
t-test 
Mean  SD Mean  SD 
Hb 
(g/dl) 
 
Control 10.95  .96  11.13  1.05 P=0.45   
Study 10.93 .95 11.28 1.10 P=0.15   
Total  
WBC 
count(/mcl) 
Control 9769.29 1628.98 9592.86 1514.60 P=0.67   
Study 9724.14 1615.47 9534.48 1583.23 P=0.56   
ESR Control 11.68  1.39 11.54 1.60 P=0.69   
Study 11.38    1.21  11.66 1.47 P=0.34   
Urea (mg/dl Control 20.79 2.692 21.29 .79 P=0.35   
Study 20.69 2.41 20.83 2.54 P=0.82   
Serum  
Creatinine(mg/dl) 
Control .78 .14 .77 .12 P=0.84   
Study .79 .14 .81 .13 P=0.69   
AST    (U/L) Control 17.64 4.52 17.50 4.04 P=0.90   
Study 17.86 4.34 17.41 4.36 P=0.71   
AST    (U/L Control 16.62 4.14 17.79 5.19 P=0.29   
Study 17.00 4.02 18.00 4.59 P=0.36   
Ck  (IU/L) Control 82.4 2.34 83 2.7 P=0.45 
Study 83 2.4 82.6 2.6 P=0.56 
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*P≤0.05 significant, ** P≤0.01 highly significant, *** P≤0.001 very high 
significant  
 
Table no 10 shows 
 The hematological and laboratory parameters of both the groups before and 
after the study. There was no significant difference in the laboratory 
parameters before and after the study in both the groups. 
 There was no significant difference in the mean SGOT and SGPT levels and 
CPK levels before and after the study in both the groups.  
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Table no 11 :  INCIDENCE OF ADVERSE EFFECTS BEFORE AND 
AFTER THE STUDY 
S.No 
 
Adverse 
effect no(%) 
Study Group 
(30) 
Control group     
(30) 
1 Nausea 2(6.66%) 2(6.66%) 
2 Dyspepsia 1(3.33%) 1(3.33%) 
3 Myalgia 2(6.66%) 3(10%) 
4 Joint pain 3(12%) 2(10%) 
 Total 8 10 
 
Table no 12: ADDITIONAL OBSERVED EFFECTS OBSERVED DURING 
THE STUDY 
S.No Beneficial effect Study Group (30) Control Group(30) 
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1 Reduced hair fall 1 0 
 
 
 
Figure no 10: Adverse effects observed during the study. 
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Table no 11  shows  
o The incidence of adverse events  observed  in both the groups during the 
study. 
o Out of 30  patients 10 patients in the control group vs 8 patients in the 
study group experienced  minor self limiting side effects. 
Figure no 10 shows a column chart representing the data of the             Table no 
11. 
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Table no 12 shows 
The additional observed  effect of biotin in the study and control group 
during the study. 
In the study group which received biotin one male patient  reported  reduced 
hair fall by the end of the fourth week of the study. 
 
 
102 
 
 
 
 
 
 
 
 
DISCUSSION 
 Dyslipidemias are one of the major causes of coronary heart disease, 
ischemic cerebrovascular disease and peripheral vascular disease which are 
induced by atherosclerosis. 
 Ever since the identification of hypercholesterolemia as a major risk 
factor for cardiovascular morbidity and mortality, drugs that modify cholesterol 
levels have been under constant research. Statins were introduced in the late 1980s 
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and now are one of the widely used  drugs. In clinical practice adherence to statins 
is mostly sub optimal due to myalgia  and other side effects like weakness, 
fatiguability and  cognitive impairment.
38  
There are not much therapeutic options 
for these statin intolerant patients.  
Other newer non statin lipid lowering drugs are under clinical trials for these 
statin intolerant patients.  They include newer drugs  like lomitapide (a microsomal 
transfer protein inhibitor), mipomersen (an antisense inhibitor of apolipoprotein B), 
and proprotein convertase subtilisin/kexin(PCSK) 9 inhibitors like evolocumab.  
 Biotin is a water soluble vitamin that acts as a prosthetic group of 
carboxylases.
39
 Biotin also regulates intermediary metabolism  at the genetic level. 
Studies in mice have proved that of biotin given in pharmacological concentrations 
reduces serum triglycerides and the expression of lipogenic genes
40
. These 
evidences and the lack of toxic effects of the vitamin at higher doses suggest that 
biotin could be used in the management of hyperlipidemias. 
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In this clinical study the therapeutic effect and side effect profile of 
combination of  Biotin 5mg  with Atorvastatin 20 mg was compared with the 
monotherapy of Atorvastatin 20 mg for 6 weeks. 
Patients with  primary  dyslipidemias will be  symptomatic at an early stage 
and have  associated cardiovascular complication. By excluding patients less than 
45 yrs of age at the screening, the possibility of inducting primary dyslipidemias is 
low. Moreover age more than 45 in males and 55 in females is considered as a 
serious risk factor for atherosclerosis. Thus, we have included only newly 
diagnosed cases with secondary dyslipidemias at high risk of atherosclerosis in the 
study. 
  In our study the mean age of the patients in the study group and control 
group were 50.13 yrs and 50.7 yrs respectively (vide table no 1 & figure no 1). 
 Though we have included patients of both sexes in the study, there was a 
female preponderance (57%) in both the groups. The sex distribution of the 
patients of both the groups were found to be same (vide table no 3 & figure no 2).  
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In our study all the patients had associated hypertension but it was of 
moderate severity and was well treated. We have included patients with type 2 
diabetes mellitus  in the study and the incidence of diabetes mellitus was 26.6% in 
control group and 23.3% in study group (vide table no 1).  
Statistical analysis has showed both the groups to be comparable in terms of 
mean age, age distribution, sex distribution, associated co-morbid diseases. 
 Patients compliance was good in both the groups with all patients 
coming for regular visits. In the study group patient follow up was good and there 
were no dropouts and all the patients completed the study. 
Effect on total cholesterol :  
Monotherapy with atorvastatin 20 mg  resulted in greater 16.7% reduction in 
total cholesterol at the end of  1
st
 week when compared to the  16.06% reduction in 
the  combination therapy group, but this was not statistically significant,  which 
implies that there are no early effects of biotin in the study group. 
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 Therafter  monotherapy resulted in  26.32% reduction in total cholesterol 
at the end of 2
nd
 week, 28.33% reduction at the end of 4
th
 week  and 28.68% 
reduction at the end of 6
th
 week. These reduction rates are similar to those 
observed in other studies by Wilinski et al.
41 
Combination therapy group showed a 34.66% reduction in total 
cholesterol at the end of the 2
nd
 week, 41.33% reduction in total cholesterol at 
the end of the 4
th
 week  and 40.37% reduction in total cholesterol at the end of 
the  6
th
 week respectively (vide table 4a&4b,figure 4 ).  
This shows that the  combination of biotin 5 mg with atorvastatin 20 mg  
resulted  in  a  greater reduction in total cholesterol from the 2
nd
 week onwards 
which was well maintained till the 6
th
 week, this difference was also statistically 
significant. 
  At the follow up visit the percentage reduction came down to 29.96% in 
the study group which was similar to the 27.56% reduction in control group 
implying that Biotin has no delayed effects on plasma lipoproteins. 
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Effects on LDL cholesterol:  
In the control group there was a 19.08% reduction in LDL levels at the first 
week, later the percentage reduction plateaued at around 34.35%, 35.89% and 
36.95% at 2
nd
, 4
th
 and 6
th
 week respectively. These reduction rates are similar to  
previous  studies showing a 25-40% reduction after treatment with Atorvastatin 20 
mg for 12 weeks.
42
  
The study group had a 16.90% reduction at 1
st
 week followed by a 39.89% 
reduction in LDL levels  at the end of  2
nd
 week, 42.62% reduction at the end 
of the  4
th
 week and 43.28% reduction at the end of the 6
th
 week. On statistical 
analysis the difference in percentage reduction in LDL levels between  the study 
group and the  control group was statistically significant at 2
nd
, 4
th
, and 6
th
 week 
(vide table 5a&5b,figure 5). 
At the follow up visit both the groups had similar reduction percentages 
35.12% in control vs. 36.57% in study group implying the absence of delayed 
effects of biotin on LDL levels. 
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Effect on triglycerides:  
The combination therapy resulted in a significantly greater reduction in 
triglyceride level from the first week onwards. The mean triglycerides were 
reduced by 13.96% at the end of 1
st
 week, 25.92% at the end of 2
nd
 week, 25.65 
at the end of  4
th
 week and 28.45% at the end of  6
th
 week in the study group 
when compared to the control group which resulted in a 5.66% reduction at the 
end of 1
st
 week, 18.34% reduction at the end of  2
nd
 week, 19.88% at the end of  
4
th
 week and 20.66% at the end of 6
th
 week. 
On statistical analysis the difference in reduction perecntages were 
statistically significant from the first week till the sixth week. 
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 At 12 weeks after Biotin was discontinued the percentage reduction of the 
study group was similar to the control group, it was 20.69% in the study group as 
against 19.36% in the control group.  
 
 
Effect on VLDL:  
The combination therapy of biotin and atorvastatin resulted in a greater 
reduction in VLDL when compared to monotherapy with atorvastatin but the 
difference was less and not statistically significant. 
Effect on HDL: 
After the 2
nd
 week of study both the groups had a rise in HDL levels . 
Though there was a greater rise in HDL percentage in the combination group it 
was not statistically significant.  
Effect on Total Cholesterol : HDL ratio:  
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The total cholesterol :HDL ratio is an important predictor of coronary artery 
risk and levels ≤ 3.5 are considered desirable and levels  > 4.5 are associated with 
higher risk. In our study the combination therapy group was able to achieve 
desirable levels of total cholesterol : HDL ratio of ≤ 3.5  at 4th and 6th weeks. In  
the monotherapy group the total cholesterol : HDL ratio was > 3.5 through out the 
study.  
Both the groups tolerated the medications and had few minor side effects. 
The incidence of  adverse  effects in the control group   was similar to those seen in 
previous studies with atorvastatin 20 mg.
43
 In the  control group 3 out of 30 
patients (10%) complained of  myalgia and  4 out of 30 patients (12%) complained 
of general body weakness. The study group had less myalgia (6.66%) and body 
weakness(10%).The occurrence of  gastrointestinal distress was  similar in both the 
groups. In addition one male patient reported reduced  hair fall during the study. 
This observation correlated with studies showing the effects  of Biotin in 
androgenic alopecia by Fameneni et al.
44,45 
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 Biotin is a very safe vitamin and levels upto 300 times the normal have 
shown to be non toxic. Thus the addition of Biotin had resulted in fewer side 
effects and some additional observed  effects also. None of the patients had any 
significant abnormality in the laboratory investigations performed. 
From this study we can infer that combination therapy of biotin and 
atorvastatin produced significantly more reduction of total cholesterol,              
LDL and triglyceride level than the monotherapy with atorvastatin.                    
This lipid lowering effect of biotin is attributed to the regulation of genes 
associated with intermediary metabolism and maintanence of glucose  and lipid 
hemostasis.
46
  
Biotin can thus be an effective and safe add on drug with Atorvastatin. It 
alone can be a valuable therapy in patients with dyslipidemia to prevent coronary 
artery disease and cerebrovascular disease and administration of biotin alone can 
be considered for further trials in dyslipidemias. 
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CONCLUSION 
It can be concluded that combination therapy of Biotin 5 mg with 
Atorvastatin 20 mg  is more efficacious  than  Atorvastatin 20 mg alone  in terms 
of reduction in Total cholesterol, LDL cholesterol and triglycerides     with less 
side effects. Thus, Biotin is a  safe  and well tolerated  adjuvant hypolipidemic 
agent in secondary dyslipidemias. 
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Appendix 1 
 
LIPID PROFILE ESTIMATION: 
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 Lipid   profile  testing   consists of estimation of Total Cholesterol,  
Triglycerides,  High Density Lipoproteins,  Low Density Lipoproteins and Very 
Low Density Lipoproteins.  Lipid   profile  estimation  was  done  in  the 
Department  of   Biochemistry. Blood  samples  for  lipid  profile  estimation was 
taken  after  12 hrs  of  fasting  at  the  beginning  of  the  study, end  of  1, 2, 4, 6  
and 12 weeks. 
A. ESTIMATION BY CHOD-PAP METHOD: 
            Cholesterol is measured enzymatically in two reactions that hydrolyze 
cholesteryl  esters  and oxidize the 3-OH group of cholesterol. One of the reaction 
byproducts H2O2 is measured quantitatively in a peroxidase catalyzed reaction 
that produces color. Absorbance is measured at 500 nm. The colour intensity is 
proportional to cholesterol concentration. 
Step 1: In the prescence of Cholesterol oxidase (CHOD)                                             
Cholesteryl ester+H2O    Cholestenone+Hydrogen peroxide 
 
Step 2: In the prescence of Phenol enzyme peroxidase(PAP) 
Hydrogen peroxide+4-amino phenazine    Coloured complex+water 
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B. ESTIMATION BY GPO-PAP METHOD 
Triglycerides   are  measured  enzymatically  in  serum  or  plasma  using  a 
series of  coupled  reactions  in  which  triglycerides  are  hydrolysed  to  produce  
glycerol. Glycerol  is  then  oxidized  using  glycerol  oxidase  and  absorbance  of  
H2O2  one  of  the  reaction  products,  is  measured  at  l500 nm. 
Step 1: In the prescence of enzyme Esterase 
Triglycerides +Water           Glycerol + Carboxylic Acid 
Step 2: In the prescence of  enzyme Glycerol Kinase 
Glycerol + ATP     Glycerol -3-Phosphate +ADP 
Step 3: In prescence of enzyme Glycerol-3-Phosphate Oxidase (GPO) 
Glycerol-3-phosphate  + Oxygen    Dihydroxy Acetone Phosphate +    
Hydrogen Peroxide. 
Step 4 :In the prescence of enzyme Peroxidase 
Hydrogen peroxide + Chlorophenol + 4-AminoPhenazone (PAP) 
                             Coloured     Complex. 
 
C. HDL CHOLESTEROL:  
HDL was measured by Direct method .  
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Principle: The  apoB  containing  lipoproteins  in  the  specimen  are  
reacted  with  a  blocking reagent  that  renders  them  non  reactive  with  the 
enzymatic  cholesterol   reagent  under  conditions  of  the  assay. The  apoB 
containing  lipoproteins  were  effectively  excluded  from  the  assay  and  only  
HDL  cholesterol  was  detected. 
The   method  uses  sulfated  alpha-cyclodextrin   in  the  presence  of   Mg
+2
,  
which  forms  complexes  with  apoB   containing  lipoproteins  and  polyethylene  
glycol – coupled  cholesteryl  esterase  and  cholesterol  oxidase  for  the  HDL-
cholesterol  measurement.   
(1)  ApoB   containing   Lipoproteins  + a-Cyclodextrin  +  Mg
+2  
+  Dextran SO 4          
forms   soluble   non-reactive   complexes   with   apoB-containing   lipoproteins.  
(2) HDL – cholesteryl  esters   in  prescence   of   PEG – cholesteryl  esterase 
forms   HDL – unesterified  cholesterol  +  fatty acid . 
(3) Unesterified   cholesterol + O2 PEG  in   prescence of   Cholesterol   Oxidase 
forms   cholestenone + H2O2  
(4) H2O2 + 5-aminophenazone + N-ethyl-N-(3-methylphenyl) – N ‟- succinyl 
ethylene diamine  +  H2O + H
+ 
peroxidase  forms  qunoneimine dye + H2O . 
Absorbance was measured at 600 nm. 
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D.LDL CHOLESTEROL: 
LDL cholesterol was calculated from measured values of total 
cholesterol,triglycerides and HHDL cholesterol according to the relation ship  
( LDL – cholesterol ) = ( Total  cholesterol ) - ( HDL – cholesterol ) - TG/5 
where   (TG)/5   is an   estimate   of   VLDL   cholesterol   and   all   values   are 
expressed   in   mg/dl. 
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CASE RECORD FORM 
 
Name    Age and Sex    Hospital number 
Complaints 
Present History 
Past History 
Personal History 
Treatment History 
General examination 
 *Pulse 
 *BP 
 *Anaemia 
 *Lymphadenopathy 
 *Pedal edema 
 *Jaundice 
Systemic examination 
 *CVS, RS  
*Abdomen 
*CNS 
INVESTIGATIONS   : Complete blood count 
Blood urea, Serum creatinine 
Plasma lipid profile(LDL,CHOLESTEROL,VLDL,TRIGLYCERIDE) 
Liver Function tests(SGOT,SGPT) 
 
CPK 
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BASELINE CHARECTERISTICS  AND  BIOCHEMICAL  PARAMETERS : 
S NO   
1 Name of the patient  
2 Age  
3 Sex  
4 IP/OP No  
5 Address for 
communication 
 
6 Drug given  
 Batch no  
 Strip no  
 Date of purchase  
7 Drug given  
 Batch no  
 Strip no  
 Date of purchase  
S 
no 
 INITIAL 1 DAY 1ST WEEK 2 WEEKS 4WEEK 6WEEK(% 
Redn 
1 LDL      
2 TRIGLY
CERID
E 
     
3 VLDL      
4 HDL      
5 CHOLE
STERO
L 
     
6 TOTAL 
PLASM
A 
LIPID 
     
7 SGOT      
8 SGPT      
9 CPK      
 
Any adverse event or additional observed effect: 
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CASE FOLLOW UP FORM 
Name    Age and Sex    Hospital number 
Complaints 
 
General examination 
 *Pulse 
 *BP 
 *Anaemia 
 *Lymphadenopathy 
 *Pedal edema 
 *Jaundice 
Systemic examination 
 *CVS ,RS  
*Abdomen 
*CNS 
INVESTIGATIONS   :  
 Complete Blood count. 
 Blood urea, Serum creatinine. 
 Liver Function tests(SGOT,SGPT). 
 CPK. 
 Fasting plasma lipid profile  
o Total cholesterol 
o LDL cholesterol 
o Triglycerides 
o VLDL 
o HDL 
Any Adverse event or additional observed effect: 
 
